

Carmen de Mendoza

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/107613/carmen-de-mendoza-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

196
papers

4,724
citations

36
h-index

57
g-index

202
ext. papers

5,272
ext. citations

5.2
avg, IF

4.93
L-index

#	Paper	IF	Citations
196	Trends in hospitalizations and deaths in HIV-Infected patients in Spain over two decades. <i>Aids</i> , 2021 , 36,	3.5	1
195	Current epidemiological status of HIV-2 and HTLV-1 infection in Spain. <i>Medicina Clínica (English Edition)</i> , 2021 , 156, 290-296	0.3	
194	Considerations on HTLV-1 infection in Spain. <i>Medicina Clínica (English Edition)</i> , 2021 , 156, 578	0.3	
193	Considerations on HTLV-1 infection in Spain. <i>Medicina Clínica</i> , 2021 , 156, 578	1	
192	Hepatitis delta in patients hospitalized in Spain (1997-2018). <i>Aids</i> , 2021 , 35, 2311-2318	3.5	1
191	Current epidemiological status of HIV-2 and HTLV-1 infection in Spain. <i>Medicina Clínica</i> , 2021 , 156, 290-296		
190	Bacterial infections in patients hospitalized with COVID-19. <i>Internal and Emergency Medicine</i> , 2021 , 1	3.7	8
189	Hepatitis C Treatment Outcomes in Persons With HIV and Decompensated Cirrhosis Using a Collaborative Multidisciplinary HIV-Centered Approach. <i>Journal of the International Association of Providers of AIDS Care</i> , 2021 , 20, 23259582211024771	1.7	0
188	Hospital admissions in individuals with HTLV-1 infection in Spain. <i>Aids</i> , 2020 , 34, 1019-1027	3.5	6
187	Inflammatory-Related Clinical and Metabolic Outcomes in COVID-19 Patients. <i>Mediators of Inflammation</i> , 2020 , 2020, 2914275	4.3	7
186	Antiretroviral Therapy for HIV-2 Infection in Non-Endemic Regions. <i>AIDS Reviews</i> , 2020 , 22, 44-56	1.5	5
185	Benefits of hepatitis C cure with antivirals: why test and treat?. <i>Future Microbiology</i> , 2019 , 14, 425-435	2.9	1
184	Treatment and prevention of HIV infection with long-acting antiretrovirals. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 507-517	3.8	29
183	Baseline NS5A resistance associated substitutions may impair DAA response in real-world hepatitis C patients. <i>Journal of Medical Virology</i> , 2018 , 90, 532-536	19.7	19
182	Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 1060-1062	2.2	11
181	Short article: Hepatitis delta in patients with resolved hepatitis B virus infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 1063-1065	2.2	5
180	HTLV infection in HCV-antibody positive patients in Spain. <i>AIDS Research and Human Retroviruses</i> , 2017 , 33, 1013-1017	1.6	

179	HIV type 2 epidemic in Spain: challenges and missing opportunities. <i>Aids</i> , 2017 , 31, 1353-1364	3.5	15
178	Human T-lymphotropic virus type 1 infection and disease in Spain. <i>Aids</i> , 2017 , 31, 1653-1663	3.5	20
177	Dual antiretroviral therapy for HIV infection. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 923-932	4.1	35
176	New antivirals for the treatment of chronic hepatitis B. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 843-851	5.9	28
175	Treatment of hepatitis C with new fixed dose combinations. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1235-1242	4	17
174	Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2083-2088	5.1	22
173	Antiretroviral treatment of HIV-2 infection. <i>Future Virology</i> , 2017 , 12, 461-472	2.4	2
172	Need to Face Liver Cirrhosis after HCV Cure with Antivirals. <i>EBioMedicine</i> , 2017 , 24, 24-25	8.8	3
171	Drug interactions in HIV-infected patients treated for hepatitis C. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 807-816	5.5	15
170	High serum HCV RNA in chronic hepatitis C patients coinfecting with HIV despite successful antiretroviral therapy. <i>Antiviral Therapy</i> , 2016 , 21, 489-494	1.6	6
169	Acute hepatitis C virus re-infection in a heterosexual HIV-positive partner. <i>Liver International</i> , 2016 , 36, 763	7.9	5
168	Delta hepatitis: new approaches to therapy. <i>Future Virology</i> , 2016 , 11, 197-205	2.4	
167	New hepatitis C therapies for special patient populations. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 217-29	4	21
166	Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child-Pugh B compensated cirrhosis. <i>Antiviral Therapy</i> , 2016 , 21, 91-2	1.6	17
165	Hepatitis C cure with antiviral therapy--benefits beyond the liver. <i>Antiviral Therapy</i> , 2016 , 21, 1-8	1.6	30
164	HUMAN T-LYMPHOTROPIC VIRUS 1 (HTLV-1) AND HUMAN T-LYMPHOTROPIC VIRUS 2 (HTLV-2): GEOGRAPHICAL RESEARCH TRENDS AND COLLABORATION NETWORKS (1989-2012). <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2016 , 58, 11	2.2	6
163	Tenofovir for Hepatitis Delta. <i>Hepatology</i> , 2016 , 63, 1395-6	11.2	6
162	Hypoglycemia in a diabetic patient during hepatitis C therapy. <i>Hepatology</i> , 2016 , 63, 2065-6	11.2	14

161	Prevention and management of treatment failure to new oral hepatitis C drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1215-23	4	42
160	Emerging challenges in managing hepatitis B in HIV patients. <i>Current HIV/AIDS Reports</i> , 2015 , 12, 344-52	5.9	19
159	Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 1421-34	4.1	13
158	Integrase inhibitor (INI) genotypic resistance in treatment-naïve and raltegravir-experienced patients infected with diverse HIV-1 clades. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 3080-6	5.1	56
157	Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C. <i>Journal of Clinical Virology</i> , 2015 , 71, 63-6	14.5	8
156	Gene therapy for HIV infection. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 319-27	5.4	7
155	Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients. <i>Antiviral Therapy</i> , 2015 , 20, 329-34	1.6	13
154	Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C. <i>Antiviral Therapy</i> , 2015 , 20, 65-72	1.6	15
153	Advances in treating drug-resistant hepatitis B virus in HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 179-86	4	5
152	Dolutegravir for the treatment of HIV-2 infection. <i>Journal of Clinical Virology</i> , 2015 , 64, 12-5	14.5	24
151	Drug interactions with new hepatitis C oral drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 333-41	5.5	44
150	Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1549-53	11.6	60
149	Dolutegravir, abacavir and lamivudine as HIV therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1051-7	1.7	8
148	Towards hepatitis C eradication from the HIV-infected population. <i>Antiviral Research</i> , 2014 , 105, 1-7	10.8	23
147	Pharmacogenetics of antiretroviral therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 1119-30	5.5	10
146	Molecular epidemiology and clinical features of human T cell lymphotropic virus type 1 infection in Spain. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, 856-62	1.6	8
145	Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies. <i>Antiviral Therapy</i> , 2014 , 19, 799-803	1.6	8
144	Spontaneous hepatitis C virus clearance in one HIV patient with chronic hepatitis C bearing IL28B-CC alleles and detectable plasma HIV-RNA. <i>Aids</i> , 2014 , 28, 2169-70	3.5	

143	Very late HCV relapse following triple therapy for hepatitis C. <i>Antiviral Therapy</i> , 2014 , 19, 723-4	1.6	4
142	Management and treatment of chronic hepatitis B in HIV-positive patients. <i>Annals of Medicine</i> , 2014 , 46, 290-6	1.5	9
141	Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. <i>Aids</i> , 2014 , 28, 2389-94	3.5	39
140	HIV-2 viral tropism influences CD4+ T cell count regardless of viral load. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2191-4	5.1	4
139	X4 tropic viruses are on the rise in recent HIV-1 seroconverters in Spain. <i>Aids</i> , 2014 , 28, 1603-9	3.5	13
138	Spontaneous hepatitis C virus clearance in HIV patients with chronic hepatitis C bearing IL28B-CC alleles using antiretroviral therapy. <i>Aids</i> , 2014 , 28, 1473-8	3.5	23
137	Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy. <i>Antiviral Therapy</i> , 2014 , 19, 287-92	1.6	5
136	HIV-2 and HTLV-1 infections in Spain, a non-endemic region. <i>AIDS Reviews</i> , 2014 , 16, 152-9	1.5	7
135	Hepatitis C therapy with HCV NS5B polymerase inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 1161-70	4	45
134	Treatment of Hepatitis C in HIV Patients in the New Era of Direct-Acting Antivirals. <i>Current Hepatitis Reports</i> , 2013 , 12, 269-275		3
133	Association between HLA alleles and HAM/TSP in individuals infected with HTLV-1. <i>Journal of Neurology</i> , 2013 , 260, 2551-5	5.5	14
132	Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy. <i>Journal of Clinical Virology</i> , 2013 , 58, 391-5	14.5	6
131	Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. <i>Aids</i> , 2013 , 27, 81-5	3.5	48
130	Hepatitis B, C, and D and HIV infections among immigrants from Equatorial Guinea living in Spain. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013 , 88, 789-94	3.2	23
129	Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 1994-2002	5.1	8
128	Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain. <i>Liver International</i> , 2013 , 33, 1357-62	7.9	36
127	Very late relapse after discontinuation of antiviral therapy for chronic hepatitis C. <i>Antiviral Therapy</i> , 2013 , 18, 1033-5	1.6	10
126	AuthorQ response: expert reviews: who are they for?. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1217-8		

125	Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. <i>Retrovirology</i> , 2012 , 9, 68	3.6	7
124	Trends in the prevalence and distribution of HTLV-1 and HTLV-2 infections in Spain. <i>Virology Journal</i> , 2012 , 9, 71	6.1	30
123	Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain. <i>Antiviral Therapy</i> , 2012 , 17, 571-5	1.6	13
122	Antiviral effect of raltegravir on HTLV-1 carriers. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 218-21	3.1	31
121	Development of tropical spastic paraparesis in human T-lymphotropic virus type 1 carriers is influenced by interleukin 28B gene polymorphisms. <i>Clinical Infectious Diseases</i> , 2012 , 55, e1-4	11.6	22
120	Evaluation of in-house genotyping assay performance using dried blood spot specimens in the Global World Health Organization laboratory network. <i>Clinical Infectious Diseases</i> , 2012 , 54 Suppl 4, S273-9	11.6	24
119	Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 2873-8	5.9	52
118	Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1007-14	4	11
117	Prevalence of xenotropic murine leukemia virus-related virus infection in different risk populations in Spain. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 1089-94	1.6	6
116	Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 156-64	1.6	17
115	Comparison of HIV-1 RNA measurements obtained by using plasma and dried blood spots in the automated abbot real-time viral load assay. <i>Journal of Clinical Microbiology</i> , 2012 , 50, 569-72	9.7	31
114	Short communication: RNASEL alleles and susceptibility to infection by human retroviruses and hepatitis viruses. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 1259-61	1.6	2
113	Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir. <i>Aids</i> , 2012 , 26, 551-7	3.5	9
112	Emerging viral infections--a potential threat for blood supply in the 21st century. <i>AIDS Reviews</i> , 2012 , 14, 279-89	1.5	19
111	Minority HIV mutation detection in dried blood spots indicates high specimen integrity and reveals hidden archived drug resistance. <i>Journal of Clinical Virology</i> , 2011 , 50, 148-52	14.5	9
110	HTLV infection among foreign pregnant women living in Spain. <i>Journal of Clinical Virology</i> , 2011 , 52, 119-25	14.5	17
109	A highly sensitive and specific model for predicting HIV-1 tropism in treatment-experienced patients combining interpretation of V3 loop sequences and clinical parameters. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 56, 51-8	3.1	8
108	Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients. <i>Antiviral Therapy</i> , 2011 , 16, 413-6	1.6	33

107	Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience. <i>Antiviral Research</i> , 2011 , 90, 164-7	10.8	45
106	Transmission of HIV drug resistance and non-B subtype distribution in the Spanish cohort of antiretroviral treatment naïve HIV-infected individuals (CoRIS). <i>Antiviral Research</i> , 2011 , 91, 150-3	10.8	28
105	Changing rate of non-B subtypes and coinfection with hepatitis B/C viruses in newly diagnosed HIV type 1 individuals in Spain. <i>AIDS Research and Human Retroviruses</i> , 2011 , 27, 633-8	1.6	14
104	HIV-1 drug resistance testing from dried blood spots collected in rural Tanzania using the ViroSeq HIV-1 Genotyping System. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 260-4	5.1	11
103	Drug resistance mutations in patients infected with HIV-2 living in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1484-8	5.1	26
102	Molecular surveillance of HIV-1 in Madrid, Spain: a phylogeographic analysis. <i>Journal of Virology</i> , 2011 , 85, 10755-63	6.6	32
101	Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 3018-20	5.9	7
100	New therapeutic strategies for raltegravir. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 218-23	5.1	8
99	Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 1493-6	5.1	33
98	Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 2502-4	5.1	17
97	Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 320-6	5.1	52
96	High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 1486-92	5.1	54
95	Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients. <i>Aids</i> , 2010 , 24, 777-9	3.5	10
94	Prevalence of HTLV-1/2 infections in Spain: A cross-sectional hospital-based survey. <i>AIDS Research and Human Retroviruses</i> , 2010 , 26, 861-4	1.6	10
93	Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database. <i>Aids</i> , 2010 , 24, 469-71	3.5	12
92	High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor. <i>Aids</i> , 2010 , 24, 467-9	3.5	28
91	Changes in drug resistance patterns following the introduction of HIV type 1 non-B subtypes in Spain. <i>AIDS Research and Human Retroviruses</i> , 2009 , 25, 967-72	1.6	14
90	Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 4153-8	5.9	6

89	Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania. <i>Clinical Infectious Diseases</i> , 2009 , 49, 976-81	11.6	78
88	Update on HIV viral-load assays: new technologies and testing in resource-limited settings. <i>Future Virology</i> , 2009 , 4, 423-430	2.4	5
87	Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests. <i>Journal of Clinical Microbiology</i> , 2009 , 47, 1031-6	9.7	58
86	Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitions. <i>Journal of Infectious Diseases</i> , 2009 , 199, 427-31	7	34
85	Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools. <i>Journal of Medical Virology</i> , 2009 , 81, 763-7	19.7	42
84	Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach. <i>Retrovirology</i> , 2009 , 6, 49	3.6	94
83	Raltegravir and etravirine are active against HIV type 1 group O. <i>AIDS Research and Human Retroviruses</i> , 2009 , 25, 225-7	1.6	39
82	Short communication: transmission of hepatitis B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals. <i>AIDS Research and Human Retroviruses</i> , 2009 , 25, 1273-6	1.6	236
81	Association between tipranavir plasma levels and virological response in HIV-infected patients. <i>AIDS Research and Human Retroviruses</i> , 2008 , 24, 389-91	1.6	3
80	Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 61, 694-8	5.1	52
79	Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir. <i>Clinical Infectious Diseases</i> , 2008 , 46, 1782-5	11.6	16
78	HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4 degrees C. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 61, 1217-20	5.1	53
77	Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. <i>Aids</i> , 2008 , 22, 611-6	3.5	33
76	Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 816-22	5.1	30
75	Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. <i>Journal of Clinical Microbiology</i> , 2008 , 46, 887-91	9.7	87
74	Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues. <i>Aids</i> , 2008 , 22, 2395-8	3.5	29
73	Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008 , 48, 241-4	3.1	35
72	Different disease progression rate according to HIV-1 subtype. <i>Future HIV Therapy</i> , 2008 , 2, 319-322		1

71	Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance. <i>Aids</i> , 2008 , 22, 311-3	3.5	6
70	Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 61, 200-5	5.1	58
69	Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. <i>Journal of Medical Virology</i> , 2007 , 79, 1040-6	19.7	39
68	Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children. <i>BMC Infectious Diseases</i> , 2007 , 7, 55	4	2
67	Evaluation of performance across the dynamic range of the Abbott RealTime HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. <i>Journal of Virological Methods</i> , 2007 , 141, 49-57	2.6	47
66	Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study. <i>AIDS Research and Human Retroviruses</i> , 2007 , 23, 1237-41	1.6	10
65	Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 60, 1411-3	5.1	8
64	Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients. <i>AIDS Research and Human Retroviruses</i> , 2007 , 23, 879-85	1.6	31
63	Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy. <i>Aids</i> , 2007 , 21, 583-8	3.5	21
62	Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 839-50	4	18
61	Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 60, 1409-10	5.1	28
60	Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 60, 885-8	5.1	52
59	Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 59, 698-704	5.1	68
58	High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. <i>Aids</i> , 2007 , 21, 2503-11	3.5	58
57	Evolution of T-cell Responses to Hepatitis C Virus (HCV) during Pegylated Interferon plus Ribavirin treatment in HCV-Monoinfected and in HCV/HIV-Coinfected Patients. <i>Antiviral Therapy</i> , 2007 , 12, 459-468	1.6	7
56	Molecular and epidemiological characteristics of blood-borne virus infections among recent immigrants in Spain. <i>Journal of Medical Virology</i> , 2006 , 78, 1599-608	19.7	26
55	Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. <i>Aids</i> , 2006 , 20, 1071-4	3.5	24
54	Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 43, 324-6	3.1	77

53	Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients. <i>AIDS Research and Human Retroviruses</i> , 2006 , 22, 1231-5	1.6	10
52	Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients. <i>HIV Clinical Trials</i> , 2006 , 7, 163-71		19
51	The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. <i>Aids</i> , 2006 , 20, 21-8	3.5	84
50	The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 41, 352-60	3.1	84
49	Estimated extent of cross-resistance to ritonavir-boosted protease inhibitors among protease inhibitors-experienced patients: implications for tipranavir use. <i>AIDS Patient Care and STDs</i> , 2005 , 19, 67-9	5.8	4
48	Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 40, 505-11	3.1	60
47	Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity. <i>HIV Clinical Trials</i> , 2005 , 6, 197-202		24
46	Relationship between drug resistance mutations, plasma viremia, and CD4+ T-cell counts in patients with chronic HIV infection. <i>Journal of Medical Virology</i> , 2005 , 76, 1-6	19.7	7
45	Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. <i>Journal of Medical Virology</i> , 2005 , 77, 23-8	19.7	20
44	Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients. <i>Journal of Medical Virology</i> , 2005 , 77, 460-4	19.7	19
43	Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. <i>Clinical Infectious Diseases</i> , 2005 , 41, 1350-4	11.6	41
42	Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1. <i>Clinical Infectious Diseases</i> , 2005 , 41, 227-32	11.6	25
41	Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption. <i>Clinical Infectious Diseases</i> , 2005 , 41, 897-900	11.6	10
40	Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. <i>Journal of Infectious Diseases</i> , 2005 , 192, 958-66	7	356
39	Treatment response and drug resistance in patients infected with HIV type 1 group O viruses. <i>AIDS Research and Human Retroviruses</i> , 2005 , 21, 602-7	1.6	15
38	Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. <i>Journal of Clinical Microbiology</i> , 2005 , 43, 3860-8	9.7	93
37	Mitochondrial DNA depletion in HIV-infected patients is more pronounced with chronic hepatitis C and enhanced following treatment with pegylated interferon plus ribavirin. <i>Antiviral Therapy</i> , 2005 , 10, 557-61	1.6	3
36	The role of hepatitis C virus (HCV) in mitochondrial DNA damage in HIV/HCV-coinfected individuals. <i>Antiviral Therapy</i> , 2005 , 10 Suppl 2, M109-15	1.6	4

35	The Role of Hepatitis C Virus (HCV) in Mitochondrial Dna Damage in HIV/HCV-Coinfected Individuals. <i>Antiviral Therapy</i> , 2005 , 10, 109-115	1.6	5
34	Mitochondrial Dna Depletion in HIV-Infected Patients is More Pronounced with Chronic Hepatitis C and Enhanced following Treatment with Pegylated Interferon plus Ribavirin. <i>Antiviral Therapy</i> , 2005 , 10, 557-561	1.6	5
33	Failure to detect human immunodeficiency virus type 1 superinfection in 28 HIV-seroconcordant individuals with high risk of reexposure to the virus. <i>AIDS Research and Human Retroviruses</i> , 2004 , 20, 1026-31	1.6	26
32	Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens. <i>AIDS Patient Care and STDs</i> , 2004 , 18, 1-6	5.8	12
31	Evidence for differences in the sexual transmission efficiency of HIV strains with distinct drug resistance genotypes. <i>Clinical Infectious Diseases</i> , 2004 , 39, 1231-8	11.6	28
30	Different viral rebound following discontinuation of antiretroviral therapy in cases of infection with viruses carrying L74V or thymidine-associated mutations. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 862-87	2	2
29	Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy. <i>AIDS Research and Human Retroviruses</i> , 2004 , 20, 271-3	1.6	33
28	Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals. <i>Journal of Virological Methods</i> , 2004 , 121, 115-8	2.6	20
27	Prevalence of drug resistance genotypes causing broad cross-resistance to nucleos(t)ide analogues. <i>Aids</i> , 2004 , 18, 689-90	3.5	4
26	Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations. <i>Aids</i> , 2004 , 18, 2094-6	3.5	33
25	Resistance to HIV protease inhibitors: mechanisms and clinical consequences. <i>Current Drug Metabolism</i> , 2004 , 5, 321-8	3.5	27
24	Could mitochondrial DNA quantitation be a surrogate marker for drug mitochondrial toxicity?. <i>AIDS Reviews</i> , 2004 , 6, 169-80	1.5	15
23	Transmission of HIV type 1 through blood transfusion from an antibody-negative/p24 antigen-negative donor. <i>AIDS Research and Human Retroviruses</i> , 2003 , 19, 447-8	1.6	3
22	Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients. <i>Journal of Clinical Microbiology</i> , 2003 , 41, 4421-3	9.7	10
21	Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy. <i>HIV Clinical Trials</i> , 2003 , 4, 361-71		16
20	Long-term outcome of HIV-infected patients with multinucleoside-resistant genotypes. <i>HIV Clinical Trials</i> , 2003 , 4, 372-81		6
19	Can drug resistance mutations influence the measurement of plasma HIV-RNA by different viral load techniques?. <i>AIDS Patient Care and STDs</i> , 2003 , 17, 321-4	5.8	1
18	Indinavir plasma concentrations and resistance mutations in patients experiencing early virological failure. <i>AIDS Research and Human Retroviruses</i> , 2003 , 19, 457-9	1.6	11

17	Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patients. <i>Journal of Clinical Microbiology</i> , 2003 , 41, 1245-7	9.7	32
16	Lamivudine resistance in human T-cell leukemia virus type 1 may be due to a polymorphism at codon 118 (V-->I) of the reverse transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 1774;author reply 1774-5	5.9	10
15	Prevalence of the HIV protease mutation N88S causing hypersensitivity to amprenavir. <i>Clinical Infectious Diseases</i> , 2002 , 34, 1288-9	11.6	3
14	Prevalence of G333D/E in naive and pretreated HIV-infected patients. <i>AIDS Research and Human Retroviruses</i> , 2002 , 18, 857-60	1.6	16
13	Evaluation of the Abbott LCx quantitative assay for measurement of human immunodeficiency virus RNA in plasma. <i>Journal of Clinical Microbiology</i> , 2002 , 40, 1518-21	9.7	23
12	Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter. <i>HIV Clinical Trials</i> , 2002 , 3, 9-16		14
11	Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families. <i>HIV Clinical Trials</i> , 2002 , 3, 304-9		38
10	Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors. <i>International Journal of Antimicrobial Agents</i> , 2002 , 20, 438-43	14.3	35
9	Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid. <i>Aids</i> , 2002 , 16, 1830-2	3.5	19
8	Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir. <i>Aids</i> , 2002 , 16, 1964-6	3.5	30
7	Mechanisms of resistance to antiretroviral drugs--clinical implications. <i>AIDS Reviews</i> , 2002 , 4, 64-82	1.5	12
6	Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. <i>Aids</i> , 2001 , 15, 1701-6	3.5	49
5	Monitoring the response to antiretroviral therapy in HIV-1 group O infected patients using two new RT-PCR assays. <i>Journal of Medical Virology</i> , 2001 , 64, 217-22	19.7	10
4	Monthly cyclic therapy in heavily pretreated HIV-infected patients. <i>AIDS Patient Care and STDs</i> , 2001 , 15, 177-9	5.8	
3	Emergence of zidovudine resistance in HIV-infected patients receiving stavudine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000 , 23, 279-81	3.1	17
2	Hydroxyurea plus didanosine as maintenance therapy after 1 year on highly active antiretroviral therapy. <i>Aids</i> , 2000 , 14, 207-8	3.5	4
1	Higher antiviral activity of antiretroviral regimens including protease inhibitors. <i>Aids</i> , 1999 , 13, 998-9	3.5	4